Answers are grounded in this paper and cite their sources.
Background CD8 + CD28 − T suppressor (Ts) cells play critical role in transplant tolerance. Our previous study has generated CD8 + CD28 − Ts cells in vitro which exert robust allospecific suppressive capacity in vitro. Results CD8 + CD28 − Ts cells were expanded by stimulating human CD8 + T cells with allogeneic antigen presenting cells in the presence of the common gamma chain cytokines IL-2, IL-7 and IL-15 in vitro, and were further verified in vitro through day 7 to 11 for their persistency of the allospecific suppressive capacity. When CD8 + CD28 − Ts cells were adoptively transferred into NOG mice, their capacity to inhibit CD4 + T cell proliferation in allospecific manner remained potent on 11 days after their injection. The mechanisms for expansion of CD8 + CD28 − Ts cells by the common gamma chain cytokines were investigated. These included promoting CD8 + CD28 − T cells proliferation, converting CD8 + CD28 + T cells to CD8 + CD28 − T cells and decreasing CD8 + CD28 − T cell death. Furthermore, the expanded CD8 + CD28 − Ts cells showed upregulation of the co-inhibitory molecule Tim-3 and down-regulation of the cytotoxic molecule granzyme B. Conclusions In summary, these results demonstrated that the in vitro-expanded human CD8 + CD28 − T cells retained potent allospecific suppressive capacity in vivo and depicted multiple mechanisms for the expansion of Ts cells, which might promote further bench to clinic research.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: